CDR-Life: bispecifics for intracellular cancer targets

CDR-Life is harnessing the high affinity of antibody fragments to develop a new class of bispecifics that can target intracellular cancer antigens.

Founded in 2017 by a group of executives that were part of the management group at antibody fragment company ESBATech AG, CDR-Life has used its experience to build a bispecific antibody platform that can engage intracellular targets via the major histocompatability complex (MHC) known as M-gager...